Fetal and Neonatal Effects of N-Acetylcysteine When Used for Neuroprotection in Maternal Chorioamnionitis  by Jenkins, Dorothea D. et al.
Fetal and Neonatal Effects of N-Acetylcysteine When Used for
Neuroprotection in Maternal Chorioamnionitis
Dorothea D. Jenkins, MD1, Donald B. Wiest, PharmD2, Denise M. Mulvihill, MD1, Anthony M. Hlavacek, MD1,
Sarah J. Majstoravich, MD1, Truman R. Brown, PhD3, Joseph J. Taylor, PhD3,4, Jason R. Buckley, MD1, Robert P. Turner, MD5,
Laura Grace Rollins, MS6, Jessica P. Bentzley, BA1, Kathryn E. Hope, MPH1, Andrew B. Barbour, PhD1, Danielle W. Lowe, BS1,
Renee H. Martin, PhD7, and Eugene Y. Chang, MD8
Objective To evaluate the clinical safety of antenatal and postnatal N-acetylcysteine (NAC) as a neuroprotective
agent in maternal chorioamnionitis in a randomized, controlled, double-blinded trial.
Study design Twenty-two mothers >24 weeks gestation presenting within 4 hours of diagnosis of clinical cho-
rioamnionitis were randomized with their 24 infants to NAC or saline treatment. Antenatal NAC (100 mg/kg/dose)
or saline was given intravenously every 6 hours until delivery. Postnatally, NAC (12.5-25 mg/kg/dose, n = 12) or sa-
line (n = 12) was given every 12 hours for 5 doses. Doppler studies of fetal umbilical and fetal and infant cerebral
blood flow, cranial ultrasounds, echocardiograms, cerebral oxygenation, electroencephalograms, and serum cyto-
kines were evaluated before and after treatment, and 12, 24, and 48 hours after birth. Magnetic resonance spec-
troscopy and diffusion imaging were performed at term age equivalent. Development was followed for cerebral
palsy or autism to 4 years of age.
Results Cardiovascular measures, cerebral blood flow velocity and vascular resistance, and cerebral oxygenation
did not differ between treatment groups. Cerebrovascular coupling was disrupted in infants with chorioamnionitis
treated with saline but preserved in infants treated with NAC, suggesting improved vascular regulation in the pres-
ence of neuroinflammation. Infants treated with NAC had higher serum anti-inflammatory interleukin-1 receptor
antagonist and lower proinflammatory vascular endothelial growth factor over time vs controls. No adverse events
related to NAC administration were noted.
Conclusions In this cohort of newborns exposed to chorioamnionitis, antenatal and postnatal NACwas safe, pre-
served cerebrovascular regulation, and increased an anti-inflammatory neuroprotective protein. (J Pediatr
2016;168:67-76).
Trial registration ClinicalTrials.gov: NCT00724594.
I
ntrauterine infection is associated with significant white and gray matter brain injury in newborns and is particularly impor-
tant in the pathogenesis of periventricular leukomalacia (PVL) and cerebral palsy.1,2 Pathogens initiate toll-like receptor
signaling in immune cells at the fetal-maternal interface, amplifying production of inflammatory cytokines in the placental
membranes and amniotic fluid.3 Subsequently, fetal inflammatory cells are activated in the cord (funisitis) and in the fetal cir-ACA Anterior cerebral artery
AE Adverse event
BA Basilar artery
BG Basal ganglia
BP Blood pressure
CBF Cerebral blood flow
CNS Central nervous system
CSF Cerebrospinal fluid
CUS Cranial ultrasound
DIC Disseminated intravascular
coagulopathy
DOL Day of life
EEG Electroencephalogram
FIRS Fetal inflammatory state
GA Gestational age
HI Hypoxic ischemic
HIE HI encephalopathy
HOL Hour of life
IL Interleukin
IL-1Ra IL-1 receptor antagonist
IVH Intraventricular hemorrhage
LPS Lipopolysaccharide
mBP Mean BP
MCA Middle cerebral artery
mI Myoinositol
MRI Magnetic resonance imaging
MRS Magnetic resonance spectroscopy
NAA N-acetylaspartate
NAC N-acetylcysteine
NEC Necrotizing enterocolitis
NO Nitric oxide
PD Pharmacodynamic
PK Pharmacokinetics
PT Prothrombin time
PVL Periventricular leukomalacia
RcSO2 Regional cerebral oxygenation
SAE Serious adverse event
TAMX Time average maximum velocity
VEGF Vascular endothelial growth factorculation, and both cytokine storm and
leukocyte and endothelial cell activation
lead to production of reactive oxygen spe-
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THE JOURNAL OF PEDIATRICS  www.jpeds.com Volume 168exposure, toll-like receptor signaling, leukocyte, and vascular
endothelial activation all contribute to a fetal inflammatory
state (FIRS) induced by chorioamnionitis. Neuroinflamma-
tion rapidly follows FIRS, within 1-4 hours in animal
models.5
Cytokines and oxidative stress may cause direct central
nervous system (CNS) injury.6,7 Oxidative stress before deliv-
ery predisposes the fetus to subsequent hypoxic ischemic
(HI) injury, even when the interruption of blood flow during
delivery is mild.8,9 Not surprisingly, the fetus frequently
shows poor tolerance to labor with heart rate decelerations
and bradycardia, which may further compromise cerebral
perfusion and exacerbate white matter injury.
N-acetylcysteine (NAC) directly scavenges oxygen free
radicals through its thiol-reducing group and is a promising
neuroprotectant in animal models of chorioamnionitis.10-13
NAC also crosses the blood brain barrier, decreases oxidative
stress and cytokine production in the CNS, and replenishes
glutathione, a major intracellular antioxidant.14,15 In an ani-
mal model of chorioamnionitis, NAC provides optimal neu-
roprotection when given antenatally.11 However, targeting
the fetal brain through the maternal circulation requires
consideration of placental metabolism and transfer, and
pharmacokinetics (PK) in the fetus and mother.
Although NAC has a favorable safety profile in human in-
fants andpregnantmotherswith acetaminophenoverdose,16,17
translational studies must carefully consider potential adverse
effects in this vulnerable population. In a fetal sheep model
of septic shock, antenatal NAC administration increased fetal
hypoxemia, raising safety concerns about its application in hu-
man chorioamnionitis.18 To address safety and possible phar-
macodynamic (PD) side effects of NAC, we conducted a
randomized, controlled pilot trial in pregnant women
$24weeks gestationwithin4hours of clinical diagnosis of cho-
rioamnionitis, and their infants postnatally. We have previ-
ously reported the PK of NAC administered to this cohort of
mothers with chorioamnionitis and in their infants.19 Intrave-
nous NAC administered to the mother undergoes rapid
placental transport, with slightly more than 1:1 transfer to
the fetus, ascertained at delivery. In this report, NAC effects
on serial cerebral bloodflow (CBF) andoximetry, cardiac func-
tion, clotting studies, and blood pressure (BP) in mothers and
infants exposed to chorioamnionitis, aswell as serumcytokines
andmagnetic resonance spectroscopy (MRS) are reportedwith
long-term outcomes.Methods
This prospective, double blinded study was approved by the
Medical University of South Carolina’s Institutional Review
Board. Written informed consent was obtained prior to
enrollment from pregnant women $24 completed weeks
gestational age (GA), who presented with a clinical diagnosis
of chorioamnionitis. Clinical chorioamnionitis was defined
as maternal fever $38

C in the presence of rupture of mem-
branes or 2 clinical findings: uterine tenderness, maternal68white blood cell >15 000 cells/mm, fetal tachycardia >160
bpm, or malodorous amniotic fluid. Maternal exclusion
criteria included bronchodilator or steroid-dependent
asthma, sepsis, seizure disorder, suspected major abnormal-
ities, fetal weight, or bi-parietal diameter less than the 10th
% for GA, or immediate delivery.
Pregnant mothers were recruited in 2 cohorts based on GA
at diagnosis of chorioamnionitis: term/late preterm ($33
completed weeks) and preterm (24-32 completed weeks).
GA cut-offs were chosen for fetal renal maturity and estimated
NAC elimination.17 After randomized to NAC or saline, NAC
(100 mg/kg/dose) or an equivalent volume of saline was given
intravenously to mothers over 60 minutes every 6 hours until
delivery. NAC/saline (preterm 12.5 mg/kg/dose; term 25 mg/
kg/dose) was administered to infants, starting 6 hours after
last maternal dose, then every 12 hours for 5 doses.
Primary safety outcomes were the incidence of histaminer-
gic reactions, clinical bleeding, hypotension, seizures, and in-
crease in prothrombin time (PT). Secondary safety outcomes
were mean BP (mBP), amount/duration of pressor support,
amount of fresh frozen plasma, seizures, and anaphylaxis.
Adverse events (AEs) were recorded for 2 days following
NAC infusion, and serious AEs (SAEs) for 30 days, verified
by an independent clinical research monitor (Table I).
Potential AEs expected with NAC treatment are
histaminergic reactions or bronchospasm in mothers, longer
PT, and lower mBP in mothers and infants. Expected
complications from chorioamnionitis are hypotension,
cardiac dysfunction, intraventricular hemorrhage (IVH),
seizures, disseminated intravascular coagulopathy (DIC),
thrombocytopenia, renal failure, pulmonary hypertension,
respiratory failure, multisystem organ failure, necrotizing
enterocolitis (NEC), PVL, and death in infants.20
Maternal clotting studies were measured before NAC infu-
sion and at delivery. Maternal blood samples for NAC serum
concentration and cytokines were drawn immediately before
and after NAC/saline infusion at 5, 15, and 30 minutes and 1,
2, 3, 4, and 6 hours, or until delivery. NAC PK were previ-
ously reported.19 Placentas and umbilical cords were graded
for chorioamnionitis and funisitis.21
All infants were evaluated for sepsis at birth, including
complete blood count and blood culture, and treated with
antibiotics by standardized clinical protocol. Clotting studies
were drawn from the cord and at 48 hours. Serial blood sam-
ples for NAC and cytokine levels were drawn from the cord,
before and at 15 minutes and 8, 12, 36, and 48 hours after the
first infant dose of NAC/saline. Lumbar puncture was per-
formed for cell count, culture, and cytokine levels before
12 hours of age, if the infant was stable without coagulopathy.
Replicate samples of serum and cerebrospinal fluid (CSF)
were prepared for cytokine analysis as previously described.22
Electroencephalograms (EEGs) were recorded during the
first dose of NAC/saline. Cranial ultrasounds (CUSs) for
IVH or other abnormalities were performed after admission
and at 48 hours (term infants) or at 7 days (preterm infants),
and magnetic resonance imaging (MRI) with MRS and diffu-
sion tensor imaging, at term age equivalent. Infants wereJenkins et al
Table I. Demographic and clinical characteristics
NAC Control Total
Entry strata
Preterm mothers: n 6 6 12
Preterm infants: n 7 7 14
GA at birth (wk) 28.2  1.7 29.4  3.3 NS
Birth weight (g) 1207  235 1339  462 NS
Term mothers: n 5 5 10
Term infants: n 5 5 10
GA at birth (wk) 38.6  2.4 38.4  2.8 NS
Birth weight (g) 3450  415 3150  582 NS
Sex infants
Male 7 6 (54%)
Female 5 6 (46%)
Race of mothers
African American 8 3 (50%)
Caucasian 3 8 (50%)
Labor and delivery
Mean duration rupture of membranes (h, range) 55  83 (0-229) 94  127 (0-322) NS
Mode of delivery
Vaginal (70%) 8 9 NS
Cesarean (29%) 4 3 NS
Maternal dosing
Mean time first maternal dose to delivery (h, range)
(excluding 2 NAC mothers who labored 17 and 32 h)
2.9  2.2 (0-7) 1.8  1.8 (0-5) NS
Maternal heart rate change pre- and 1 h postdosing (bpm) 1.8  17 2.5  18 NS
Maternal mBP change pre and postdosing (mm Hg) 1  12 2  10 NS
Maternal hypotension 1 1
Fetal tachycardia first noted postdosing 1 0
Maternal mean PT (s) predose 13.7  0.5 14.0  0.9 NS
Maternal mean PT (s) at delivery 14.2  0.6 14.1  1.2 NS
Mean change PT (s) after dose 0.51  0.5 0.45  0.2 NS
Histopathology (missing 3)
Maternal inflammatory response, any grade 12/12 (100%) 8/9 (89%)
Fetal inflammatory response, any grade funisitis 9/12 (75%) 5/9 (56%)
Infant
Apgar at 1 min, median 6  2.0 6.3  2.7 NS
Apgar at 5 min, median 7.9  1.8 7.5  2.5 NS
Cord pH, mean 7.27  0.08 7.22  0.16 NS
WBC (Kcells/mm3) at birth, mean 14.4  5.0 8.1  6.3 NS
Absolute neutrophil count (cells/mm3) at birth, mean 8.9  6.2 10.8  5.3 NS
Culture proven sepsis/pneumonia at birth 1 1
PT (s), mean DOL 1 19.5  2.5 19.0  4.0 NS
SAEs
Infant resuscitation-chest compressions/CV meds 0 1
Death 0 1
PVL/IVH at birth 1 0
IVH from 1-2 d of age 1 1
IVH from 5-7 d of age 2 0
NEC within 30 d 1 1
CV, cardiovascular; NS, not significant; WBC, white blood cells.
January 2016 ORIGINAL ARTICLESfollowed in neonatal follow-up clinic at 12-24 months of age
and at 3-4 years by the infants’ general and developmental pe-
diatricians.
Doppler blood flow was measured before and after dosing
in the umbilical and/or fetal middle cerebral artery (MCA)
prior to delivery when possible, and postnatally in the ante-
rior cerebral artery (ACA), MCA, and basilar artery (BA)
before and after the first dose (0-6 hours of life [HOLs]),
and at 12, 24, 36, and 48 hours. Near-infrared spectroscopy
probe placed over the forehead recorded regional cerebral
oxygenation (RcSO2) during and after NAC/saline dosing,
at 0-6, 12, 24, 36, and 48 HOLs. Echocardiograms were per-
formed before the first dose and at 12, 24, and 48 HOLs. NAC
assay was previously reported, with maternal and infant NACFetal and Neonatal Effects of N-Acetylcysteine When Used for Nplasma concentrations and PK, determined by high perfor-
mance liquid chromatography.14,19 Intravenous NAC
administration in the mother undergoes rapid placental
transfer, and PK of NAC are different in preterm and term
infants.19
Additional details for the Methods section are available in
the Appendix (available at www.jpeds.com).
Statistical Analyses
Univariate analysis of variables between groups was per-
formed using unpaired Student t test or Kruskal-Wallis tests.
Repeated measures were analyzed by ANOVA or generalized
linear mixed models as appropriate. Spearman or Pearson
correlations were performed for analyses with NAC plasmaeuroprotection in Maternal Chorioamnionitis 69
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designated as P < .05 to minimize type II error in measures
of drug safety, without corrections for multiple comparisons.
For cytokines, logarithmic transformations were performed
before statistical analysis. In assessment of beneficial effects
of NAC within treatment groups, multiple comparisons
adjusted with Bonferroni correction are also reported.Results
Twenty-two mothers (12 preterm, 10 term) and 24 infants,
including 2 sets of twins, were enrolled from August 2008 to
January 2010. There were no significant differences in demo-
graphic data between the group treatedwithNAC and controls
(Table I). No participant met stop criteria for drug infusion.
Two withdrawals occurred: one for maternal preference and
one infant treated with NAC for IVH and cystic changes on
CUS. The infant was withdrawn from study prior to first
NAC dose, and CUS findings were consistent with an event
occurring more than a week prior to delivery.
Seventeen mothers had epidural anesthesia, all with
rupture of membrane and other signs of chorioamnionitis.
Histologic examination of placentas demonstrated 13 had
both maternal and fetal inflammatory response; 5 had
maternal inflammatory response alone; 2 placentas from
the second twin in twin pregnancies had no inflammation;
and 4 placentas were missing.
Additional details for the Results section are available in
the Appendix (available at www.jpeds.com).
Maternal/Fetal AEs
There were no differences in maternal AEs between the
group treated with NAC or saline. Hypotension during de-
livery (1 mother treated with NAC and 1 control), resolved
with phenylephrine and volume expansion. One mother
treated with NAC had an urticarial rash, but no anaphylac-
toid reactions were noted. Maternal heart rate, BP, and PTs
did not show significant changes pre- and post-NAC dosing
or over time between mothers treated with NAC and con-
trols (Table I), and did not correlate with NAC
concentrations. A single maternal SAE was reported in a
control mother at 24 weeks GA with hypotension, fetal
heart rate abnormalities, purulent amniotic fluid, severe
necrotizing chorioamnionitis, and trivascular funisitis. Her
infant died in the delivery room with severe mixed
acidosis (cord pH <6.8, base deficit 24).
Fetal Hemodynamics
Twomothers (1 mother treated with NAC and 1 control) had
nonreassuring fetal heart rate tracings, with late decelerations
and fetal bradycardia. One mother treated with NAC with
39.4C had new-onset fetal tachycardia. Fetal metabolic
acidosis was not different between groups (Table I).
Umbilical cordbloodflowwasmeasuredpredosing (n=13),
and postdosing (n = 10; NAC 8, saline 2), and remained stable
without reversal of flow indiastole.Mean cordpulsatility index70was similar pre-NAC (1.16  0.28, 95% CI) and post-NAC
(1.12  0.15, 95% CI, n = 8). Fetal MCA blood flow was
measured pre- (n = 8) and postdosing (n = 6; NAC 4, saline
2) (Figure 1; available at www.jpeds.com). Preterm and term
fetuses treated with NAC had no evidence of systemic or
cardiac compromise in utero. An increase in fetal MCA time
average maximum velocity (TAMX) after NAC dosing was
observed in the 4 preterm fetuses.
Infant AEs
Eight infants had SAEs (Table I). Sepsis-related events were
death (1 control), listeria sepsis (1 control), and
pneumonia at birth (1 NAC). All CSF cultures were
negative. NEC before 30 days of life (DOLs) occurred in 1
NAC and 1 control infant. Late NEC developed in 1 infant
treated with NAC with Escherichia coli sepsis and grade IV
IVH (DOL 35), PVL (DOL 45), cerebral palsy, and
cognitive deficits at 4 years.
PT was not significantly different in infants treated with
NAC or saline (Table I). At birth, PT was >18 seconds in
50% preterm infants (2 infants treated with NAC and 2
controls out of 8 preterm infants with clotting studies at
birth), and one-quarter of term infants (1 infant treated
with NAC with HI encephalopathy [HIE] out of 4 term
infants with clotting studies at birth). Overall, 57% infants
with clotting studies within 48 hours of birth had PT
>18 seconds (3/6 control; 5/8 NAC). Two infants treated
with NAC and 1 control received fresh frozen plasma.
In total 4 preterm infants had IVH grades II-III during first
week of life, 3 had DIC at birth (2 infants treated with NAC
and 1 control). One infant treated with NAC had grade I IVH
bilaterally with cystic changes at 4.5 HOL, consistent with an
intrauterine event prior to study drug infusion. NAC was un-
detectable in this infant’s cord blood, and coagulation studies
clotted.
Hemodynamic Variables in Infants
Cardiovascular measures (heart rate, systolic, diastolic, mBP)
were not significant between treatment groups or before and
after study drug dosing (Figure 2). No infant required
vasopressors during the period of NAC infusion. Cord,
pre-, or postinfusion NAC plasma concentrations showed
no PD correlation with BP measurements.
Infant CBF Velocity and Vascular Resistance
Mean CBF in cerebral vessels were not significantly different
before or after dosing or between treatment groups in either
GA cohort (Figure 3). However, CBF velocity increased and
resistance decreased significantly very early in the MCA
(0 hour to 12-24 hours) in all preterm and term infants
exposed to chorioamnionitis, and by 24 hours in the ACA
in preterm infants. The timing of the changes were earlier
than previous reports in normal24 and preterm infants
exposed to chorioamnionitis (24-40 hours), and similar to
preterm infants who developed IVH.25 Male sex had a
significant effect on MCA (P = .014) and BA resistance
(P = .032), which varied by GA (Figure 4; available atJenkins et al
Figure 2. Systolic, diastolic, and mBPs before and after first NAC/saline dose (0-6 HOLs) by GA. Reference line represents
normal BP measure for first week of life by GA.23 P, preterm infants; T, term infants.
January 2016 ORIGINAL ARTICLESwww.jpeds.com). CBF and cardiac measures were not
significantly different in preterm infants with (n = 4) and
without IVH (n = 7) (Figure 5; available at www.jpeds.com).
NAC Maintains Normal Cerebral Arterial
Relationships despite Chorioamnionitis
Resistive indices and blood flow velocities are normally
tightly correlated in the major cerebral vessels of an individ-
ual.24 Chorioamnionitis disrupts this tight correlation in
term infants,26 and blood flow in different regions of the
brain may be affected by neuroinflammatory factors and
increased metabolic demand. NAC can restore cerebral au-
toregulation and nitric oxide (NO) responsiveness.27,28 We
investigated the pattern of CBF correlation in ACA, MCA,
and BA in individual infants, for beneficial effects of NAC
on neuroinflammation-induced disruption of CBF. CBF ve-
locities in the MCA were strongly associated with those in
ACA (P = .0003) and BA (P = .003) in the group treated
with NAC from 0-48 hours of the study, but not in the con-
trol group. Resistance in the ACA was also significantly asso-
ciated with MCA (P = .001) and BA (P = .0004) in the group
treated with NAC, but marginally associated with MCA
(P = .018) in the control group over time. With Bonferroni
correction for 4 mixed model comparisons within treatment
groups (MCA and ACA, TAMX and corrected resistive index,
P < .0125), all NAC associations remained significant.
Cardiac Function and Cerebral Oxygenation
Mean echocardiographic measurements were not signifi-
cantly different between treatment groups before and after
the first dose of NAC or at 12, 24, and 48 hours in either
GA cohort (Figure 6; available at www.jpeds.com) and did
not correlate with NAC serum concentrations. NAC
administration had no main effect on left ventricular
output myocardial performance index or velocity, ejectionFetal and Neonatal Effects of N-Acetylcysteine When Used for Nfraction, or stroke volume.29 Importantly, male sex had a
significant negative effect on ejection fraction in these
infants exposed to chorioamnionitis (P = .0027).
Near-infrared spectroscopy data were adequate in 7 term
and 10 preterm infants, and there were no differences in
oxygenation before, during, or after NAC dosing or over
time compared with controls. Mean RcSO2 was marginally
associated with cardiac output (r = 0.24, P = .05), but not
with other indices of cardiac function. In preterm infants
exposed to chorioamnionitis, higher RcSO2 in the frontal
lobes in the first 6 hours was associated with lower resistance
in the ACA (P = .031), adjusting for HOL and GA. The dura-
tion of maternal fever prior to birth also correlated with
higher RcSO2 in their infants for the first 12 hours, regardless
of GA (r $ 0.67, P < .007, n = 15-16). Taken together, our
findings suggest that neuroinflammation may determine
local vasodilation and RcSO2.
30
EEG
No electrographic or clinical seizures were recorded in either
group. Nine infants treated with NAC and 7 controls had
adequate serial EEG tracings for dosing effects. Three infants
treated with NAC had abnormal background activity (low
amplitude) before NAC dose, which normalized in 2 infants
during the NAC infusion. One infant treated with NAC
showed persistent low amplitude.
MRI
MRI at term age equivalent had low apparent diffusion coef-
ficients in the posterior limb of the internal capsule in 1 pre-
term infant treated with NAC and 1 control. Both had
normal outcomes. The term infant with HIE treated with
NAC had abnormal signal intensities in basal ganglia (BG)
bilaterally, but normal Bayley-III scores at 12 months and
normal development at 2 years of age.europrotection in Maternal Chorioamnionitis 71
Figure 3. A, Infant CBF velocity (TAMX) and resistive indices (corrected resistive index [CRI]) in the ACA, MCA, and BA before
and after initial dose of NAC or saline in preterm (n = 6 NAC, n = 5 control), and B, term (n = 5 NAC, n = 4 control) cohorts (mean,
95% CI). No significant differences in TAMX or CRI between NAC and control infants in any vessel. *P < .016; †P < .007; zP < .05,
all versus predosing (0 hour).
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in the BG showed a weak trend, with control infants having
higher mI/NAA ratios than infants treated with NAC, con-
trolling for GA at birth (P = .08, n = 16). In the preterm
group, BG mean mI/NAA ratios were higher in control
(1.4  0.23; n = 6) than preterm infants treated with NAC
(0.92  0.30; n = 4) exposed to chorioamnionitis
(P = .026). Higher mI ratios are associated with astrogliosis,
and lower NAA ratios are associated with neuronal injury.31
There were no significant differences in fractional anisotropy
in the corpus callosum or internal capsule in infants scanned
at term age equivalent, controlling for GA at birth and scan.
Cytokines
Median and IQRs for cytokines from maternal serum at de-
livery, infant cord serum, and infant CSF samples are re-72ported by treatment group (Table II; available at www.
jpeds.com). Serum fibroblast growth factor 2 (FGF2)
concentrations were significantly lower in mothers treated
with NAC compared with the saline group over time
(Figure 7, A), and interleukin (IL)-17 decreased after
dosing only in the group treated with NAC (P = .01). FGF2
is produced by activated endothelial cells, and potentiates
leukocyte recruitment and extravasation at sites of
inflammation.32 IL-17 is secreted by a subset of T helper
cells-17, which are responsive to bacterial infection and
inflammation.33
Infants treated with NAC had significantly lower serum
proinflammatory vascular endothelial growth factor
(VEGF) and higher anti-inflammatory IL-1 receptor
antagonist (IL-1Ra) over time compared with controls
(Figure 7, B). For IL-1Ra and IL-6, treatment-timeJenkins et al
Figure 7. Median, IQR of serum cytokine concentrations (pg/
mL): A, FGF-2 before and after NAC/saline dosing in mothers
(NAC n = 11; saline n = 7, P = .02); B, VEGF and IL-1Ra in
infants over 0-48 hours after delivery with GA and time in
mixed model (n = 12 NAC, n = 9 saline; P # .014). For IL-6,
there was a significant NAC treatment*time interaction effect
(P = .014), from 36-48 HOL. FGF-2, fibroblast growth factor 2.
January 2016 ORIGINAL ARTICLESinteractions were evident, and IL-6 was lower at 36 and
48 hours in infants treated with NAC vs controls. Our
infant serum IL-6 concentrations were similar to
published values in preterm infants exposed to
chorioamnionitis with fetal inflammatory response andFetal and Neonatal Effects of N-Acetylcysteine When Used for Nearly sepsis (>40 pg/mL)34 and in preterm infants with
white matter injury.35 VEGF contributes to early brain
injury as a permeability factor associated with blood
brain barrier disruption, hemorrhage, and ischemia.36
Anti-inflammatory IL-1Ra provides significant
neuroprotection in animal models of chorioamnionitis
and HI injury, by blocking IL-1b activity, leukocyte
infiltration, and microglial activation.37 Consistent with
these data, lower serum IL-1Ra was associated with
higher mI/creatinine in the white matter in our infants
(n = 13, r = 0.73; P = .01). There were no significant
differences between treatment groups in CSF cytokines
obtained within 12 hours of birth, controlling for GA
(n = 16).
Serum IL-6, IL-8, VEGF, and monocyte chemotactic
protein-1 were also significantly related toMCA CBF velocity
over the 48 hours of the study in a mixed model with HOL,
treatment, and GA (all P # .03, n = 20 subjects, 91 paired
CBF/cytokine observations from 0-48 hours). These data
are consistent with the roles of these cytokines as biomarkers
of endothelial activation and injury.
Developmental Outcomes
Twenty-one infants exposed to chorioamnionitis were
available for follow-up to 3-4 years of age (9 controls and
12 infants treated with NAC). Two out of 9 control infants
had developmental delay; 1 preterm infant with IVH had
speech delay at 3 years, and 1 preterm infant with NEC
had fine motor delay at 4 years. Two of the 12 infants treated
with NAC had delays; 1 preterm infant with late NEC, grade
4 IVH, and PVL, had spastic quadriplegia and cognitive
impairment, and 1 preterm infant had fine motor delay
and autism spectrum disorder at 4 years.Discussion
In this pilot study of neuroprotection in preterm and
term infants exposed to chorioamnionitis, NAC adminis-
tration antenatally in the mother and postnatally to their
infants, resulted in no significant adverse effects on CBF,
cerebral oxygenation, cardiac function, clotting measure-
ments, or BP. Infants treated with NAC did show benefi-
cial effects, as NAC restored normal cerebrovascular
coupling between major cerebral vessels, decreased proin-
flammatory VEGF, and increased anti-inflammatory IL-
1Ra compared with infants who received saline. Mothers
treated with NAC also had lower cytokines associated
with endothelial activation and leukocyte recruitment
during inflammation. Fetal systemic inflammatory
response with elevated circulating IL-6 and clotting ab-
normalities occurred in the majority of infants, strongly
suggesting the presence of fetal endothelial activation
and neuroinflammation.
In human infants and animal models of chorioamnioni-
tis, FIRS and neuroinflammation cause injury to the CNS
and other organs by direct toxicity of cytokine mediators,europrotection in Maternal Chorioamnionitis 73
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autoregulation, which occur very early after infection.
Vascular endothelial injury results in dysregulation of fetal
and neonatal CBF,8,38 as we saw with decreased cerebrovas-
cular resistance and increased CBF within 12-24 hours,
particularly in males. Furthermore, the immediate loss of
correlation of CBF and resistance between the 3 major cere-
bral vessels after birth is consistent with intrauterine onset
of neuroinflammation and vascular dysfunction.26,39
Although we did not include a control group of preterm
and term infants without chorioamnionitis exposure,
another report has found uncoupling of CBF and resistance
in term neonates exposed to chorioamnionitis, compared
with term infants not exposed to chorioamnionitis.26
Also, abnormal CBF has been documented in early onset
sepsis and in preterm infants who develop IVH.25,30 Fetal
inflammatory cascades also predispose term and preterm
infants to significant morbidities of IVH, HIE, white matter
injury, and NEC, in which vascular insufficiency may be a
contributing factor.25,30
Antenatal NAC can counteract fetal neuroinflammation
associated with chorioamnionitis by several mechanisms,
including scavenging oxygen free radicals, restoring intracel-
lular glutathione levels, and decreasing inflammatory cyto-
kine production.10-13 NAC stabilizes CBF, enhances
autoregulation, and re-establishes normal vascular reactivity,
which depends on endothelial synthesis of NO.27,40 NAC in-
hibits conversion of NO to peroxynitrite, thereby preserving
the bioavailability of NO for normal vascular responsiveness
under oxidative stress.27,41
NAC also had no untoward effects on cerebral or sys-
temic perfusion in the fetus or infant when started within
4 hours of clinical diagnosis of chorioamnionitis and
administered for the first 48 hours after birth. In a similar
time frame in adult patients with endotoxic shock, NAC
increased cardiac output index, oxygen delivery, and sys-
temic vascular resistance.42 However, NAC effects are
more variable when started later than 24 hours in sepsis.43
Furthermore, high dose NAC has been associated with
reduced left ventricular stroke work in a small number
of adult patients, when given more than 24 hours from
onset of septic shock.44 If present in excess, NAC sulfhy-
dryl groups may react with NO to form S-nitrosothiols, a
stable, stored form of NO that can cause vasodilation.45
Although treatment was instituted within 4 hours of
chorioamnionitis in our study, we considered that NAC
could interact with specific vulnerabilities of fetal and
neonatal physiology to produce hypotension. With exten-
sive physiologic monitoring before and after NAC dosing,
we found no adverse hemodynamic changes with 100 mg/
kg in mothers or 12.5-25 mg/kg/dose NAC administered to
their infants compared with saline treatment. Fetuses had
significant NAC plasma concentrations, but umbilical
and CBF velocities were stable before and after maternal
NAC dosing.19
We found no differences in infant BP or RcSO2 over 2 days
of dosing between NAC and saline-treated infants, contrary74to a report in fetal sheep.18 In this model of septic shock, daily
lipopolysaccharide (LPS) administration was followed by a 5-
hour infusion of 50, 100, or 200 mg/kg NAC for 5 days (n = 2
per dose),18 which causes significant hypoxemia and hypo-
tension for 3-24 hours in this model.46 When comparing ef-
fect of NAC, most of the significant hemodynamic
differences were between sham and LPS animals in the mixed
model. In post hoc analyses, NAC-LPS animals showed small
changes of questionable clinical significance in partial pres-
sure of oxygen in arterial blood, pH, lactate, and mBP
compared with LPS-saline animals.18
NAC plasma concentrations and cerebral perfusion were
not measured in the fetal sheep, which inhibits a PD com-
parison with our human study, but NAC dose did not
correlate with the changes.18 In our infants, NAC did not
adversely affect systemic perfusion, cardiac function, or
CBF before and after NAC dosing, or over 48 hours
compared with control infants exposed to chorioamnioni-
tis. None of the PD measurements of hemodynamic, cere-
bral perfusion, or cardiac variables correlated with
concurrent NAC plasma concentrations. This indicates
that these PD measures are not influenced by NAC at the
doses used in infants exposed to chorioamnionitis.
The small sample size in this intensive safety study is a po-
tential limitation. However, other studies have documented
no AEs in fetuses of mothers who received NAC for acet-
aminophen overdose, or in very preterm infants who
received NAC continuously for the first 6 DOLs to prevent
bronchopulmonary dysplasia.16,17 Our incidence of NEC
and IVH after chorioamnionitis is similar to other reports,
but our sample size is not large enough to evaluate effects
of NAC treatment on these complications. Infants treated
with NAC had no greater adverse outcomes related to early
events than control infants.
More than one-half of our infants with clotting studies had
significant DIC within the first 24 hours after birth, indepen-
dent of treatment. Coagulopathy has been noted in other re-
ports in 25%-30% of infants exposed to chorioamnionitis,
and provides laboratory evidence of systemic inflammatory
response with endothelial activation.47,48 In addition, these
findings suggest that clotting abnormalities and early in-
creases in CBF may contribute to greater incidence of IVH
and neurodevelopmental delays in infants exposed to cho-
rioamnionitis.25
Although our sample size is limited, we did not see
threshold or concentration-dependent adverse effects of
NAC on CBF, cardiac function, or cerebral oxygenation.
Neuroprotective compounds that can be used in this popula-
tion are rare, and these data support further evaluation of
NAC for antenatal neuroprotection.
For antenatal drug administration to be effective in
future treatment trials for chorioamnionitis, consider-
ation should be given to length of the consent
process in laboring mothers and the short duration of la-
bor in term mothers with chorioamnionitis. However,
our PK data show that even a short infusion of NAC
rapidly crosses the placenta and can be measured inJenkins et al
January 2016 ORIGINAL ARTICLESthe cord blood of the neonate, making antenatal admin-
istration of NAC feasible for fetal neuroprotection in
chorioamnionitis.19 n
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Luke MJ. J Pediatr 1966;68:90-102
Valvular pulmonic stenosis (PS) with an intact ventricular septum is a common congenital heart defect that oftenpresents in infancy. When the obstruction is severe, this malformation can be extremely dangerous and if left
untreated, may be fatal. In 1966, a review by Luke reported of the fate of 36 cases of severe PS. Most infants were
asymptomatic initially but progressively developed cyanosis, hepatomegaly, poor feeding, delayed motor develop-
ment, and failure to thrive. The initial workup included a heart catheterization for diagnostic purposes, and revealed
extremely elevated right ventricular pressures. All patients required open heart surgery. Fourteen of the 36 patients
died (39%). Six died prior to surgery, 7 shortly after surgery, and there was 1 late death.
Fifty years after this report was published, echocardiograms provide the necessary information to make the diag-
nosis. The cardiac catheterization is therapeutic rather than diagnostic. A balloon catheter is used to dilate the pulmo-
nary valve, thus avoiding open heart surgery. The mortality from PS with an intact ventricular septum is less than 1%.
The next chapter in the treatment of pulmonary valve disease is the development of a heart valve implanted through
a catheter in a leg vein and guided up to the heart, thus avoiding open heart surgery in cases where the valve needs to be
replaced. This procedure is commonly available in pediatric cardiac centers.
As suggested by Luke, early recognition of PS remains important, but once the diagnosis is made, the treatments and
outcomes are vastly improved, allowing these infants to thrive.
Reginald L. Washington, MD
Rocky Mountain Hospital for Children
Denver, Colorado
http://dx.doi.org/10.1016/j.jpeds.2015.07.051Jenkins et al
Appendix
Methods
Consent was initially obtained within 4 hours of onset of fe-
ver, but delivery frequently occurred before study procedures
could be completed. With Institutional Review Board
approval, we obtained prequalifying consent from women
in preterm labor or with ruptured membranes.
Enrollment/randomization was initiated only if inclu-
sion criteria were met. Enrollment was constrained by
the time to obtained informed consent in actively laboring
women, late presentation/diagnosis of chorioamnionitis in
term mothers, and by emergent delivery. Of 111 patients
approached but not enrolled, reasons included inadequate
time between the qualifying temperature and infant deliv-
ery (n = 56); temperature elevation <38C (n = 16); met
exclusion criteria (bronchodilator dependent asthma,
participation in another trial, n = 17); or declined partic-
ipation (n = 22). Seventeen mothers had epidural anes-
thesia: in 2, fever onset preceded epidural placement,
and in 6, fever onset was 9-24 hours after epidural place-
ment. Preterm mothers received magnesium for neuropro-
tection as standard of care. Obstetrical decisions regarding
delivery were not altered for study procedures.
For mothers, criteria to immediately stop N-acetylcysteine
(NAC) infusion included seizure, maternal hypotension
(blood pressure [BP] <90/60, after fluid bolus), broncho-
spasm requiring inhaled beta-agonists, angioedema requiring
diphenhydramine, anaphylaxis, or clinical bleeding episode
with disseminated intravascular coagulopathy (DIC)
requiring fresh frozen plasma (FFP).
For infants, criteria to immediately stop NAC infusion
included seizures, refractory hypotension, bronchospasm,
or DIC (prothrombin time [PT] $19; fibrinogen <100 mg/
dL) unresponsive to FFP.
Electroencephalograms (Electrocap international Inc, Ea-
ton, Ohio) were recorded during the first dose of NAC/saline,
and read by a single pediatric neurologist.
Cerebral blood flow (CBF) studies obtained pulsatility in-
dex, time averaged maximum velocity, and resistive index
(systolic velocity-diastolic velocity/systolic velocity), cor-
rected for heart rate, were averaged over 5-beat intervals. A
single pediatric radiologist verified quality and analysis of
Doppler spectra.
Near-infrared spectroscopy probe placed over the fore-
head (INVOS 4100, Covidien, Ltd, Mansfield, Massachu-
setts) recorded regional cerebral oxygenation (RcSO2)
continuously after admission (preterm), or before, during
and after drug administration (term infants) to allow breast-
feeding and other interactions with parents. A minimum of
20 minutes continuous RcSO2 data were analyzed before,
during, and after NAC/saline dosing, at 0-6, 12, 24, 36, and
48 hours of life (HOLs). Abrupt changes from baseline
<60 seconds in duration were omitted.
Echocardiograms were performed before the first dose of
study drug (Philips iE33; Philips Medical Systems, Andover,
Massachusetts) and at 12, 24, and 48 HOLs during the drug
infusion, and read by a single pediatric cardiologist. Superior
vena cava (SVC) flowwasmeasured according to the following
algorithm [SVC flow = (SVC-velocity time integral * pr2 *
heart rate)/weight]. Left ventricular dimensions and contrac-
tility measurements consisted of 3-dimensional ejection frac-
tion, stroke volume index (stroke volume/weight), cardiac
output index ([stroke volume*heart rate]/weight), left ventric-
ular annular systolic myocardial velocity (LVASMV), and left
ventricular myocardial performance index (LVMPI).
Serum was separated, and serum and cerebrospinal fluid
samples were stored at 70C until analysis. Cytokine anal-
ysis was performed using Milliplex bead assays (HCTOMAG,
NDG4, HNDG2, HNDG3, HCYP2MAG; EMD Millipore,
Billerica,Massachusetts) on a BioPlex system (BioRad; Lumi-
nex Technology, Hercules, California).
Developmental follow-up was assessed with infant neuro-
developmental screening, gross motor function, clinical
auditory, and language assessments (CAT/CLAMS), Bayley
III, and/or Vineland testing in neonatal follow-up clinic at
12-24 months of age. Cerebral palsy, developmental delay,
autism spectrum disorder, and learning disabilities were as-
sessed at 4 years by the infants’ general and developmental
pediatricians. Sixteen infants returned for neurodevelop-
mental testing at neonatal follow-up clinic, and 5 were seen
by their developmental specialist or pediatrician for develop-
mental testing.
Statistical Analyses. Summary descriptive statistics were
performed for frequency, severity, and duration of adverse
events (AEs). Maternal heart rate and BP, fetal CBF, and in-
fant BP were analyzed by ANOVA before and after dosing
between treatment groups and by gestational age (GA) co-
horts. Infant CBF, echocardiographic, and RcSO2 were
analyzed over time using generalized linear mixed models
with repeated measures and GA in the model, as appro-
priate. Spearman or Pearson correlations defined the rela-
tionship of potential pharmacodynamic variables to NAC
plasma concentrations. For cytokines, median values and
IQRs are reported (nonparametric data), and logarithmic
transformations were performed before statistical analysis.
Statistics were performed with SAS v 9.2 (SAS Institute,
Cary, North Carolina) and R v 3.1.0 (R Development
Core Team; designed by Ross Ihaka and Robert Gentleman).
Results
Peak NAC serum levels did not correlate with mean or dia-
stolic BP measurements in mothers, 1-3 hours after NAC.
There were no episodes of postpartum bleeding, and PT at de-
livery did not correlate with serum NAC concentrations in
mothers. A single maternal serious AE was reported in a con-
trol mother who had rales, wheezing, and hypotension; puru-
lent amniotic fluid and fetal heart rate abnormalities were
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noted during her urgent cesarean delivery for fetal heart rate
abnormalities. Her 24-week GA infant died in the delivery
room with severe mixed acidosis (cord pH <6.8, base deficit
24). Placental pathology demonstrated severe necrotizing cho-
rioamnionitis and trivascular funisitis. Infant blood cultures
were negative, as the mother received antibiotics.
Fifty-seven percent of the infants with clotting studies had
PT >18 seconds (3/6 control; 5/8 NAC). At birth, PT was
>18 seconds in 4 out of 8 preterm infants (2 infants treated
with NAC and 2 controls), and 1 out of 4 term infants with
clotting studies. The term infant treated with NAC had severe
hypoxic ischemic (HI) encephalopathy. FFP was infused for
DIC in 2 infants treated with NAC and 1 control infant.
Three preterm infants with DIC developed intraventric-
ular hemorrhage (IVH) (2 infants treated with NAC and 1
control). In total, 4 preterm infants had IVH during first
week of life. Cranial ultrasound within 24 hours of birth
showed grade II IVH in 1 infant treated with NAC and grade
III IVH in 1 control infant, both of whom had DIC at birth.
Between day of life (DOL) 5 and 7, 1 preterm infant treated
with NAC had unilateral small grade II IVH, and 1 infant
treated with NAC had grade II/III IVH after requiring FFP
for DIC at birth. One infant with NAC had grade I IVH bilat-
erally with cystic changes at 4.5 HOL, consistent with an in-
trauterine event prior to study drug infusion. NAC was
undetectable in this infant’s cord blood, and coagulation
studies clotted. Only 3 infants with IVH also had near-
infrared spectroscopy data.
One term infant with NAC had shoulder dystocia
requiring vacuum extraction, subgaleal and subdural hemor-
rhages, severe HI encephalopathy treated with hypothermia,
and Erb palsy. Abnormal T1 shortening was present in
thalami and the basal ganglia bilaterally, consistent with HI
injury. Other serious AEs included postnatally diagnosed
multicystic kidney disease (1 infant treated with NAC), and
ectopic atrial tachycardia treated with propranolol (1 con-
trol).
Necrotizing enterocolitis (NEC) before 30 DOLs occurred
in 2 infants. One control infant had medical NEC at DOL 14,
requiring antibiotics and bowel rest for 14 days. The second
NEC case occurred on DOL 6 in a 30 week GA infant, deliv-
ered with severe acidosis (pH 6.92) after rupture of mem-
branes for 9 days with active maternal Escherichia coli
urinary tract infection and chorioamnionitis. This infant
treated with NAC had just been advanced to 24 calorie/ounce
preterm formula on a feeding protocol. Surgical resection re-
sulted in short gut syndrome and placement of a gastrostomy
tube. Late NEC developed in 1 infant treated with NAC on
DOL 35 with E coli sepsis, hypotension, and renal and respi-
ratory failure. This infant progressed to grade IV IVH at DOL
36 with periventricular leukomalacia at DOL 45 and had ce-
rebral palsy and cognitive deficits at 4 years.
NAC treatment had no main effect on echocardiographic
measures, but treatment had an interaction effect with
HOL in determining stroke volume (P = .013), with different
patterns of stroke volume over time in NAC and saline in-
fants. NAC serum concentrations (cord, predosing trough,
peak, 12, or 48 hours) did not show pharmacodynamic cor-
relations with predosing, 12-, 24-, or 48-hour cardiac vari-
ables in either GA cohort. Importantly, left ventricular
output measures (LVASMV or LVMPI), take into account
both diastolic and systolic periods and are independent of
heart rate, BP or geometric assumptions inherent in other
cardiac output measures, and were not different between
treatment groups. As expected, LVASMV and LVMPI were
significantly different in preterm and term infants
(P < .002). Cardiac output index and stroke volume were
different by GA with an interaction effect with HOL
(P # .02). Patent ductus arteriosus was found in all preterm
infants during the first 2 DOLs, and persisted in 1 infant
treated with NAC and 1 control at DOL 7, requiring indo-
methacin.
Using a mixed model with log transformed cytokines, GA,
time, and an interaction term for GA and treatment, serum
levels of fibroblast growth factor 2 were significantly lower
over time in mothers treated with NAC compared with those
receiving saline (Figure 6, A). IL-17 concentrations were
significantly lower in mothers treated with NAC at all time
points including before dosing, but decreased after dosing
only in the group receiving NAC (P = .01).
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Figure 1. Mean fetal umbilical cord andMCAblood flow velocity (TAMX) before and after NAC dosing by treatment andGA (n = 4
preterm, n = 2-3 term) with 95% CIs. Doppler measures could not be obtained in preterm control fetuses.
Figure 4. CRIs in BA and MCA over 48 HOLs by sex for individual preterm and term infants, regardless of treatment (preterm:
n = 6 females, n = 5 males; term: n = 5 females, n = 4 males). Preterm males have higher CRI than females, whereas term males
have lower CRI than females, as previously reported by Koch et al.26 CRI, corrected resistive index.
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Figure 5. A, CBF and B, cardiac function in preterm infants with IVH in the first week of life vs those with no insult (mean, 95%
confidence intervals, CI). A,CBF velocity (TAMX) and resistance (CRI) in ACA, MCA, and BA before and after treatment with NAC
or saline (n = 4 IVH, n = 7 control). B, Echocardiographic measurements before and after NAC/saline (n = 4 IVH, n = 7 control). All
were not significant. CO, cardiac output index (ml/kg/min); EF, ejection fraction; LVASMV (mL/s); StokeVol, stroke volume index
(mL/kg); SVCFlow, superior vena cava flow velocity (mL/kg/min).
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Figure 6. Echocardiographic measures before and after dosing of NAC or saline in preterm and term infants. Cardiac output
(mL/kg/min), EF, LVASMV (mL/s,) and LVMPI, stroke volume (mL/kg), and SVC flow (mL/kg/min) were not significantly different
before or after dosing of NAC or saline (mean, 95% CI; preterm: n = 6 NAC, n = 5 control; term: n = 4 NAC, n = 4 control).
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Table II. Cytokine concentrations by treatment group
(median, IQR, pg/mL)
NAC Control
Maternal
cytokines
at delivery
CKine 446 (212-912) 181 (77-317)
Eotaxin 46 (20-81) 37 (31-44)
FGF2 7.6 (7.6-26) 26 (9.2-93)
Fractalkine 23 (23-23) 41 (25-69)
GCSF 1345 (357-3932) 729 (218-2050)
GMCSF 7.8 (7.5-9.3) 11 (8.4-25)
GRO 1574 (1520-2083) 944 (787-1566)
IL-1a 9.4 (9.4-9.4) 9.4 (9.4-17)
IL-1Ra 8.3 (8.3-11) 8.3 (8.3-8.3)
IL-6 81 (53-407) 35 (17-157)
IL-7 4.4 (1.4-12) 4.5 (2.5-8.8)
IL-8 13 (6.3-35) 38 (17-65)
IL-10 48.89 (30-352) 132 (38-198)
IL-17 0.7 (0.7-3.0) 20 (9.9-161)
IL-23 37 (32-51) 45 (32-305)
IP10 386 (226-564) 245 (192-506)
LIF 6.0 (5.8-7.2) 6.8 (6.3-17)
MCP1 626 (371-1640) 1018 (333-1114)
MCP2 34 (30-41) 21 (16-34)
MCP4 51 (37-84) 21 (14-58)
MDC 923 (790-953) 699 (500-864)
MIP1a 3.4 (2.9-5.5) 3.8 (2.9-7.2)
MIP1b 43 (33-64) 48 (25-103)
MIP1d 5835 (4266-7965) 6074 (3062-7351)
sCD40L 18 703 (9597-29 332) 5000 (2630-11 719)
sDF1ab 1950 (1141-2643) 831 (173-1724)
sIL-2RA 11 (11-11) 11 (11-36)
TPO 201 (178-446) 116 (77-730)
VEGF 40 (26-129) 209 (26-468)
Cord serum
cytokines
CKine 1562 (991-1948) 689 (100-846)
Eotaxin 41 (19-80) 57 (42-71)
FGF2 26 (14-77) 22 (15-76)
Fractalkine 42 (24-60) 28 (24-40)
GCSF 3995 (821-14 423) 827 (176-3618)
GMCSF 7.5 (7.5-12) 7.5 (7.5-7.9)
GRO 2092 (1253-2521) 1151 (966-1570)
IL-1a 9.4 (9.4-22) 9.4 (9.4-9.4)
IL-1Ra 745 (251-1302) 8.3 (8.3-448)
IL-6 125 (53-212) 71 (9.9-195)
IL-7 1.4 (1.4-2.1) 1.4 (1.4-6.4)
IL-8 114 (40-392) 96 (11-139)
IL-10 27 (4.0-107) 4.7 (2.2-32)
IL-17 0.7 (0.7-0.7) 0.7 (0.7-3.4)
IL-23 32 (32-32) 32 (32-32)
IP10 294 (176-589) 255 (194-320)
LIF 8.4 (5.8-14) 15 (7.8-19)
MCP1 887 (725-2882) 1034 (728-1124)
MCP2 39 (33-48) 47 (44-69)
MCP4 85 (49-108) 52 (46-86)
MDC 1517 (946-1988) 1223 (1022-2327)
MIP1a 30 (9.7-88) 11 (9.6-25)
MIP1b 105 (86-143) 88 (85-98)
MIP1d 11 234 (9796-12 754) 11 693 (9968-13 114)
sCD40L 30 619 (20 426-56 028) 18 430 (15 865-40 696)
sDF1ab 2247 (1034-2546) 2582 (383-2981)
sIL2RA 187 (57-230) 11 (11-193)
TPO 269 (89-420) 224 (120-593)
VEGF 69 (26-233) 241 (234-293)
Infant CSF
cytokines
Cathepsin D 34 577 (29 711-38 967) 33 890 (28 619-44 022)
Complement
C4
1419 (1295-1448) 1618 (1162-1981)
CRP 54 (16-121) 48 (12-179)
(continued )
Table II. Continued
NAC Control
FGF2 7.6 (7.6-9.1) 11 (7.9-14)
Flt3L 36 (30-43) 38 (30-41)
Fractalkine 49 (45-59) 56 (51-67)
GCSF 36 (24-224) 46 (35-199)
GRO 36 (32-105) 67 (38-137)
IL-1b 0.8 (0.8-0.8) 0.8 (0.8-0.8)
IL-1Ra 8.7 (8.3-26) 8.3 (8.3-8.9)
IL-2 1.0 (1.0-1.0) 1.1 (1.0-1.2)
IL-6 6.2 (0.9-18) 3.5 (1.5-4.5)
IL-7 3.7 (2.3-5.9) 4.9 (3.9-6.1)
IL-8 403 (243-2239) 876 (408-1735)
IL-10 4.9 (3.0-5.2) 6.2 (2.9-7.7)
IL-17 0.7 (0.7-0.7) 0.7 (0.7-0.7)
IP10 262 (219-357) 333 (266-1535)
MCP1 4359 (2962-5688) 5360 (4504-6168)
MDC 3.6 (3.6-5.5) 3.6 (3.6-3.6)
MIP1a 6.8 (5.5-12) 4.4 (3.5-13)
MIP1b 29 (18-31) 25 (16-41)
MIP4 0.2 (0.1-0.2) 0.1 (0.1-0.2)
NCAM 199 685 (17 8413-269 305) 171 580 (148 688-240 162)
PAI1 total 5221 (2009-16 333) 4053 (2998-4883)
PDGF AA 65 (37-82) 53 (48-104)
PEDF 845 (754-931) 796 (752-955)
S100b 471 (427-652) 453 (395-808)
sCD40L 5.1 (5.1-38) 5.1 (5.1-5.1)
sICAM1 1257 (1071-2443) 1130 (1029-2088)
sIL-2Ra 11 (11-11) 11 (11-11)
sVCAM1 358 857 (261 649-428 756) 353 097 (276 063-373 702)
VEGF 26 (26-26) 26 (26-26)
CKine, secondary lymphoid-tissue chemokine; FGF2, fibroblast growth factor 2; GCSF, granu-
locyte colony stimulating factor; GM-CSF, granulocyte monocyte colony stimulating factor;
GROa, (CXCL1) growth regulated protein alpha; IP10, interferon gamma inducible protein 10;
LIF, leukemia inhibitory factor; MCP, monocyte chemotactic factor; MIP, macrophage inflam-
matory protein; sCD, soluble cluster of differentiation antige; sDF, stromal cell-derived factor;
TPO, thyroid peroxidase; CRP, C-reactive protein; FLT3L, FMS-like tyrosine kinase 3 ligand;
MCD, macrophage-derived chemokine; NCAM, neural cell adhesion molecule; sICAM1, soluble
intercellular adhesion molecule; sVCAM, soluble vascular cell adhesion molecule; PAI1, plas-
minogen activator inhibitor 1; PDGF AA, Platelet-derived growth factor-AA; PEDF, pigment
epithelium-derived factor; S100b, S100 calcium binding protein B.
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